References

nmp

Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»

Russian Sklifosovsky Journal "Emergency Medical Care"

2223-90222541-8017

“N.V. Sklifosovsky Research Institute for Emergency Medicine”

10.23934/2223-9022-2023-12-4-625-636

nmp-1726

Research Article

ОБЗОР ЛИТЕРАТУРЫ

REVIEWS

Использование белков-маркеров NSE, S100-B, GFAP в диагностике и лечении ишемии головного мозга у пациентов с аневризматическим субарахноидальным кровоизлиянием

The Use of Neuromarker NSE, S100-B, GFAP Proteins in the Diagnosis and Treatment of Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage

https://orcid.org/0000-0003-4518-9874

Лукьянчиков

В. А.

Lukyanchikov

V. A.

Виктор Александрович Лукьянчиков, доктор медицинских наук, профессор, врач-нейрохирург, главный врач

кафедра нейрохирургии и нейрореанимации

127473

ул. Делегатская, д. 20, стр. 1

127349

ул. Мурановская, д. 5

Москва

Victor A. Lukyanchikov, Doctor of Medical Sciences, Professor, Head Physician

Department of Neurosurgery and Neuroresuscitation

127473

20, bldg. 1, Delegatskaya Str.

127349

5, Muranovskaya Str.

Moscow

vik-luk@yandex.ru

https://orcid.org/0000-0001-9612-6705

Годков

М. А.

Godkov

M. A.

Михаил Андреевич Годков, доктор медицинских наук, профессор, заведующий отделом, заведующий лабораторией

научный отдел лабораторной диагностики

клинико-диагностическая лаборатория № 1

129090

Б. Сухаревская пл., д. 3

Москва

Mikhail A. Godkov, Doctor of Medical Sciences, Professor, Head of the Department, Head of the Laboratory

Department of Laboratory Diagnostics

Clinical Diagnostic Laboratory No. 1

129090

3, Bolshaya Sukharevskaya Sq.

Moscow

mgodkov@yandex.ru

https://orcid.org/0000-0002-4273-9378

Гордеев

И. Ю.

Gordeev

I. Yu.

Игорь Юрьевич Гордеев, аспирант, врач-нейрохирург

кафедра нейрохирургии и нейрореанимации

127473

ул. Делегатская, д. 20, стр. 1

115516

ул. Бакинская, д. 26

Москва

Igor Yu. Gordeev, Resident, Neurosurgeon

Department of Neurosurgery and Neuroresuscitation

127473

20, bldg. 1, Delegatskaya Str.

115516

26, Bakinskaya Str.

Moscow

batkakr@yandex.ru

https://orcid.org/0000-0003-1895-9714

Вайман

Е. С.

Vayman

E. S.

Екатерина Сергеевна Вайман, аспирант, младший научный сотрудник

кафедра нейрохирургии и нейрореанимации

127473

ул. Делегатская, д. 20, стр. 1

отделение неотложной нейрохирургии

129090

Б. Сухаревская пл., д. 3

Москва

Ekaterina S. Vayman, Resident, Junior Researcher

Department of Neurosurgery and Neuroresuscitation

127473

20, bldg. 1, Delegatskaya Str.

Department of Emergency Neurosurgery

129090

3, Bolshaya Sukharevskaya Sq.

Moscow

safovitch@yandex.ru

ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» МЗ РФ; ООО «ГК ЮНИ Клиник»РоссияA.I. Yevdokimov Moscow State University of Medicine and Dentistry; Clinical Center UNICLINICRussian Federation

ГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского ДЗМ»РоссияN.V. Sklifosovsky Research Institute for Emergency MedicineRussian Federation

ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» МЗ РФ; ГБУЗ «Городская клиническая больница им. В.М. Буянова ДЗМ»РоссияA.I. Yevdokimov Moscow State University of Medicine and Dentistry; V.M. Buyanov City Clinical HospitalRussian Federation

ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» МЗ РФ; ГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского ДЗМ»РоссияA.I. Yevdokimov Moscow State University of Medicine and Dentistry; N.V. Sklifosovsky Research Institute for Emergency MedicineRussian Federation

2023

22012024

124625636

2024

Лукьянчиков В.А., Годков М.А., Гордеев И.Ю., Вайман Е.С.

Lukyanchikov V.A., Godkov M.A., Gordeev I.Y., Vayman E.S.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.jnmp.ru/jour/article/view/1726

Частота возникновения нетравматического субарахноидального кровоизлияния вследствие разрыва аневризм сосудов головного мозга и последующая инвалидизация мотивируют к поиску предикторов тяжелого течения и неблагоприятного исхода заболевания для раннего интенсивного лечения. В нейродиагностике зарекомендовали себя маркеры NSE, S100-B, GFAP для оценки динамики лечения заболеваний нервной системы и обнаружения неврологических нозологий.Применение вышеуказанных белков при аневризматическом кровоизлиянии открывает новые перспективы в оценке клинического статуса пациента на ранних этапах, дальнейшей тактике лечения, помогает делать выводы об исходе заболевания и возможной инвалидизации пациента. Исследования, собранные в обзоре, мотивируют к продолжению изучения нейромаркеров при аневризматическом кровоизлиянии.

The incidence of non-traumatic subarachnoid hemorrhage due to rupture of cerebral aneurysms and subsequent disability motivates the search for predictors of severe course and unfavorable outcome of the disease for early intensive treatment. NSE, S100-B, GFAP markers have proven themselves well for assessing the dynamics of treatment for diseases of the nervous system and detecting neurological nosologies. The use of the above proteins in aneurysmal hemorrhage opens up new perspectives in assessing the clinical status of the patient in the early stages, developing further treatment strategies, as well as helps draw conclusions about the outcome of the disease and possible disability of the patient. The studies collected in the review motivate continued research of the neuromarkers in aneurysmal hemorrhage.

субарахноидальное кровоизлияниенейромаркеры при нетравматическом субарахноидальном кровоизлиянииS100-BNSEGFAPпрогностические факторы нетравматического субарахноидального кровоизлияния

subarachnoid hemorrhageneuromarkers of nontraumatic subarachnoid hemorrhageS100-BNSEGFAPprognostic factors of nontraumatic subarachnoid hemorrhage

Исследование не имеет спонсорской поддержки

The study has no sponsorship

References1

Скворцова В.И., Стаховская Л.В., Айриян Н.Ю. Эпидемиология инсульта в Российской Федерации. Системные гипертензии. 2005;(1):10–12.

van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306–318. PMID: 17258671. doi: 10.1016/S0140-6736(07)60153-6.

Bowles E. Cerebral aneurysm and aneurysmal subarachnoid haemorrhage. Nurs Stand. 2014;28(34):52–59. PMID: 24749614. doi: 10.7748/ns2014.04.28.34.52.e8694.

Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. 2006;355(9):928–939. PMID: 16943405. doi: 10.1056/NEJMra052760.

Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies : a systematic review. Lancet Neurol. 2009;8(4):355–369. PMID: 19233729. doi: 10.1016/S1474-4422(09)70025-0.

Давыдов В.В., Комаров О.С.; Шестопалов А.В. (ред.). Биохимия нервной ткани : учебно-методическое пособие. Москва: Белый ветер; 2018.

Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull. 1995;37(4):417–429. PMID: 7620916. doi: 10.1016/0361-9230(95)00040-2.

Hayashi K, Hoshida Y, Horie Y, Takahashi K, Taguchi K, Sonobe H, et al. Immunohistochemical study on the distribution of alpha and beta subunits of S-100 protein in brain tumors. Acta Neuropathol. 1991;81(6):657–663. PMID: 1882640. doi: 10.1007/BF00296376.

Michetti F, Miani N, De Renzis G, Caniglia A, Correr S. Nuclear localization of S-100 protein. J Neurochem. 1974;22(2):239–244. PMID: 4208418. doi: 10.1111/j.1471-4159.1974.tb11585.x.

Moss S. E. (ed.). The annexins. London&Chapel Hill: Portland Press; 1992.

Zimmer DB, Van Eldik LJ. Identification of a molecular target for the calcium-modulated protein S100. Fructose-1,6-bisphosphate aldolase. J Biol Chem. 1986;261(24):11424–11428. PMID: 3733759

Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, et al. S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008–1022. doi: 10.1016/j.bbamcr.2008.11.009. Epub 2008 Dec 7. PMID: 19110011.

Skripnikova EV, Gusev NB. Interaction of smooth muscle caldesmon with S-100 protein. FEBS Lett. 1989;257(2):380–382. PMID: 2531095. doi: 10.1016/0014-5793(89)81577-7.

Wilder PT, Rustandi RR, Drohat AC, Weber DJ. S100B(betabeta) inhibits the protein kinase C-dependent phosphorylation of a peptide derived from p53 in a Ca2+-dependent manner. Protein Sci. 1998;7(3):794–798. PMID: 9541413. doi: 10.1002/pro.5560070330.

Gentil BJ, Delphin C, Mbele GO, Deloulme JC, Ferro M, Garin J, et al. The giant protein AHNAK is a specific target for the calcium- and zinc-binding S100B protein: potential implications for Ca2+ homeostasis regulation by S100B. J Biol Chem. 2001;276(26):23253–23261. PMID: 11312263. doi: 10.1074/jbc.M010655200.

Michetti F, D’Ambrosi N, Toesca A, Puglisi MA, Serrano A, Marchese E, et al. The S100B story: from biomarker to active factor in neural injury. J Neurochem. 2019;148(2):168–187. PMID: 30144068. doi: 10.1111/jnc.14574.

Gazzolo D, Florio P, Ciotti S, Marinoni E, di Iorio R, Bruschettini M, et al. S100B protein in urine of preterm newborns with ominous outcome. Pediatr Res. 2005;58(6):1170–1174. PMID: 16306188. doi: 10.1203/01.pdr.0000185131.22985.30.

Florio P, Michetti F, Bruschettini M, Lituania M, Bruschettini P, Severi FM, et al. Amniotic fluid S100B protein in mid-gestation and intrauterine fetal death. Lancet. 2004;364(9430):270–272. PMID: 15262105. doi: 10.1016/S0140-6736(04)16677-4.

Gazzolo D, Lituania M, Bruschettini M, Ciotti S, Sacchi R, Serra G, et al. S100B protein levels in saliva: correlation with gestational age in normal term and preterm newborns. Clin Biochem. 2005;38(3):229–233. PMID: 15708543. doi: 10.1016/j.clinbiochem.2004.12.006.

Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease. Biochim Biophys Acta Mol Cell Res. 2020;1867(6):118677. PMID: 32057918. doi: 10.1016/j.bbamcr.2020.118677.

Astrand R, Undén J, Romner B. Clinical use of the calcium-binding S100B protein. Methods Mol Biol. 2013;963:373–384. PMID: 23296623. doi: 10.1007/978-1-62703-230-8_23.

Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, Hernandez N, et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia. 2007;48(4):732–742. PMID: 17319915. doi: 10.1111/j.1528-1167.2007.00988.x.

Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, Barnett G, et al. Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption. J Neurosci. 2003;23(5):1949–1955. PMID: 12629200. doi: 10.1523/JNEUROSCI.23-05-01949.2003.

Сосновский А.Ю. Применение маркера протеина S100 B в диагностике и прогнозировании исходов лечения черепно-мозговой травмы : автореферат дис. … канд. мед. наук. Москва, 2014. URL: https://search.rsl.ru/ru/record/01005557615 [Дата обращения 15. 12. 2023]

Marangos PJ, Schmechel D, Parma AM, Clark RL, Goodwin FK. Measurement of neuron-specific (NSE) and non-neuronal (NNE) isoenzymes of enolase in rat, monkey and human nervous tissue. J Neurochem. 1979;33(1):319–329. PMID: 110910. doi: 10.1111/j.1471-4159.1979.tb11735.x.

Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature. 1978;276(5690):834–836. PMID: 31568. doi: 10.1038/276834a0.

Ishiguro Y, Kato K, Ito T, Nagaya M, Yamada N, Sugito T. Nervous system-specific enolase in serum as a marker for neuroblastoma. Pediatrics. PMID: 6356007. 1983;72(5):696–700.

Carney DN, Teeling M. Neuron-specific enolase: how useful as a cancer marker? Eur J Cancer Clin Oncol. 1988;24(5):825–828. PMID: 3049114. doi: 10.1016/0277-5379(88)90190-3.

Hans P, Bonhomme V, Collette J, Moonen G. Neuron-specific enolase as a marker of in vitro neuronal damage. Part I: Assessment of neuron-specific enolase as a quantitative and specific marker of neuronal damage. J Neurosurg Anesthesiol. 1993;5(2):111–116. PMID: 8490308. doi: 10.1097/00008506-199304000-00007.

Czupryna P, Grygorczuk S, Pancewicz S, Świerzbińska R, Zajkowska J, Krawczuk K, et al. Evaluation of NSE and S100B in patients with tick-borne encephalitis. Brain Behav. 2018;8(12):e01160. PMID: 30468006. doi: 10.1002/brb3.1160.

Snoer AH, Vollesen ALH, Beske RP, Guo S, Hoffmann J, Jørgensen NR, et al. S100B and NSE in Cluster Headache – Evidence for Glial Cell Activation? Headache. 2020;60(8):1569–1580. PMID: 32548854. doi: 10.1111/head.13864.

Yilmaz S. Serum NO, S100B, NSE concentrations in migraine and their relationship. J Clin Neurosci. 2020;82(Pt A):32–35. PMID: 33317735. doi: 10.1016/j.jocn.2020.10.046.

Sun J, Li J, Cheng G, Sha B, Zhou W. Effects of hypothermia on NSE and S-100 protein levels in CSF in neonates following hypoxic/ischaemic brain damage. Acta Paediatr. 2012;101(8):e316–e320. PMID: 22452413. doi: 10.1111/j.1651-2227.2012.02679.x.

Inoue S, Takahashi H, Kaneko K. The fluctuations of neuron-specific enolase (NSE) levels of cerebrospinal fluid during bacterial meningitis: the relationship between the fluctuations of NSE levels and neurological complications or outcome. Acta Paediatr Jpn. 1994;36(5):485–488. PMID: 7825447. doi: 10.1111/j.1442-200x.1994.tb03230.x.

Krohn M, Dreßler J, Bauer M, Schober K, Franke H, Ondruschka B. Immunohistochemical investigation of S100 and NSE in cases of traumatic brain injury and its application for survival time determination. J Neurotrauma. 2015;32(7):430–440. PMID: 25211554. doi: 10.1089/neu.2014.3524.

Топузова М.П., Алексеева Т.М., Панина Е.Б., Вавилова Т.В., Ковзелев П.Д., Портик О.А. и др. Возможность использования нейрон-специфической енолазы как биомаркера в остром периоде инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(8-2):53–62. doi: 10.17116/jnevro201911908253

Kim BJ, Kim YJ, Ahn SH, Kim NY, Kang DW, Kim JS, et al. The second elevation of neuron-specific enolase peak after ischemic stroke is associated with hemorrhagic transformation. J Stroke Cerebrovasc Dis. 2014;23(9):2437–2443. PMID: 25183561. doi: 10.1016/j.jstrokecerebrovasdis.2014.05.020.

Cunningham RT, Watt M, Winder J, McKinstry S, Lawson JT, Johnston CF, et al. Serum neurone-specific enolase as an indicator of stroke volume. Eur J Clin Invest. 1996;26(4):298–303. PMID: 8732487. doi: 10.1046/j.1365-2362.1996.129282.x.

Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res. 2000;25(9–10):1439–1451. PMID: 11059815. doi: 10.1023/a:1007677003387.

Mokuno K, Kamholz J, Behrman T, Black C, Sessa M, Feinstein D, et al. Neuronal modulation of Schwann cell glial fibrillary acidic protein (GFAP). J Neurosci Res. 1989;23(4):396–405. PMID: 2769798. doi: 10.1002/jnr.490230405.

Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364–374. PMID: 25975510. doi: 10.1016/j.tins.2015.04.003.

Roelofs RF, Fischer DF, Houtman SH, Sluijs JA, Van Haren W, Van Leeuwen FW, et al. Adult human subventricular, subgranular, and subpial zones contain astrocytes with a specialized intermediate filament cytoskeleton. Glia. 2005;52(4):289–300. PMID: 16001427. doi: 10.1002/glia.20243.

Li D, Liu X, Liu T, Liu H, Tong L, Jia S, et al. Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytes. Glia. 2020;68(5):878–897. PMID: 31626364. doi: 10.1002/glia.23734.

Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res. 2015;1600:17–31. PMID: 25543069. doi: 10.1016/j.brainres.2014.12.027.

Aebi U, Häner M, Troncoso J, Eichner R, Engel A. Unifying principles in intermediate filament (IF) structure and assembly. Protoplasma. 1988;145(2–3):73–81. doi: 10.1007/BF01349341

Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421–443. PMID: 21219963. doi: 10.1016/j.pneurobio.2011.01.005.

Nakamura Y, Takeda M, Angelides KJ, Tada K, Hariguchi S, Nishimura T. Assembly, disassembly, and exchange of glial fibrillary acidic protein. Glia. 1991;4(1):101–110. PMID: 1828780. doi: 10.1002/glia.440040112.

Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenström H. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999;45(1):138–141. PMID: 9895354.

Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4(3):229–237. PMID: 7952264. doi: 10.1111/j.1750-3639.1994.tb00838.x.

Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy. 2005;4(3):335–340. PMID: 16101543. doi: 10.2174/1568010054022051.

Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32(12):638–647. PMID: 19782411. doi: 10.1016/j.tins.2009.08.002.

Papa L, Brophy GM, Welch RD, Lewis LM, Braga CF, Tan CN, et al. Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury. JAMA Neurol. 2016;73(5):551–560. PMID: 27018834. doi: 10.1001/jamaneurol.2016.0039.

Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. 2010;75(20):1786–1793. PMID: 21079180. doi: 10.1212/WNL.0b013e3181fd62d2.

Kassubek R, Gorges M, Schocke M, Hagenston VAM, Huss A, Ludolph AC, et al. GFAP in early multiple sclerosis: A biomarker for inflammation. Neurosci Lett. 2017;657:166–170. PMID: 28802830. doi: 10.1016/j.neulet.2017.07.050.

Yoshida T, Nakagawa M. Clinical aspects and pathology of Alexander disease, and morphological and functional alteration of astrocytes induced by GFAP mutation. Neuropathology. 2012;32(4):440–446. PMID: 22118268. doi: 10.1111/j.1440-1789.2011.01268.x.

Sellner J, Patel A, Dassan P, Brown MM, Petzold A. Hyperacute detection of neurofilament heavy chain in serum following stroke: a transient sign. Neurochem Res. 2011;36(12):2287–2291. PMID: 21792676. doi: 10.1007/s11064-011-0553-8.

Marginean IC, Stanca DM, Vacaras V, Soritau O, Margiean M, Muresanu DF. Plasmatic markers in hemorrhagic stroke. J Med Life. 2011;4(2):148–150. PMID: 21776296.

Simani L, Elmi M, Asadollahi M. Serum GFAP level: A novel adjunctive diagnostic test in differentiate epileptic seizures from psychogenic attacks. Seizure. 2018;61:41–44. PMID: 30077862. doi: 10.1016/j.seizure.2018.07.010.

Clairembault T, Kamphuis W, Leclair-Visonneau L, Rolli-Derkinderen M, Coron E, Neunlist M, et al. Enteric GFAP expression and phosphorylation in Parkinson’s disease. J Neurochem. 2014;130(6):805–815. PMID: 24749759. doi: 10.1111/jnc.12742.

Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009;80(5):575–577. PMID: 19372295. doi: 10.1136/jnnp.2008.150698.

Foerch C, Curdt I, Yan B, Dvorak F, Hermans M, Berkefeld J, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry. 2006;77(2):181–184. PMID: 16174653. doi: 10.1136/jnnp.2005.074823.

Dvorak F, Haberer I, Sitzer M, Foerch C. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis. 2009;27(1):37–41. PMID: 19018136. doi: 10.1159/000172632.

Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta. 2004;342(1–2):1–12. PMID: 15026262. doi: 10.1016/j.cccn.2003.12.008.

Wunderlich MT, Wallesch CW, Goertler M. Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke. Eur J Neurol. 2006;13(10):1118–1123. PMID: 16987165. doi: 10.1111/j.1468-1331.2006.01435.x.

van Bodegraven EJ, van Asperen JV, Robe PAJ, Hol EM. Importance of GFAP isoform-specific analyses in astrocytoma. Glia. 2019;67(8):1417–1433. PMID: 30667110. doi: 10.1002/glia.23594.

Kaneda K, Fujita M, Yamashita S, Kaneko T, Kawamura Y, Izumi T, et al. Prognostic value of biochemical markers of brain damage and oxidative stress in post-surgical aneurysmal subarachnoid hemorrhage patients. Brain Res Bull. 2010;81(1):173–177. PMID: 19887101. doi: 10.1016/j.brainresbull.2009.10.020.

Kedziora J, Burzynska M, Gozdzik W, Kübler A, Kobylinska K, Adamik B. Biomarkers of Neurological Outcome After Aneurysmal Subarachnoid Hemorrhage as Early Predictors at Discharge from an Intensive Care Unit. Neurocrit Care. 2021;34(3):856–866. PMID: 32978732. doi: 10.1007/s12028-020-01110-2.

Vos PE, van Gils M, Beems T, Zimmerman C, Verbeek MM. Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity. Eur J Neurol. 2006;13(6):632–638. PMID: 16796588. doi: 10.1111/j.1468-1331.2006.01332.x.

Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology. 2004;62(8):1303–1310. PMID: 15111666. doi: 10.1212/01.wnl.0000120550.00643.dc.

van Geel WJ, de Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta. 2002;326(1–2):151–154. PMID: 12417106. doi: 10.1016/s0009-8981(02)00330-3.

Jennett B, Snoek J, Bond MR, Brooks N. Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry. 1981;44(4):285–293. PMID: 6453957. doi: 10.1136/jnnp.44.4.285.

Teasdale GM, Drake CG, Hunt W, Kassell N, Sano K, Pertuiset B, et al. A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. J Neurol Neurosurg Psychiatry. 1988;51(11):1457. PMID: 3236024. doi: 10.1136/jnnp.51.11.1457.

Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6(1):1–9. PMID: 7354892. doi: 10.1227/00006123-198001000-00001.

Mabe H, Suzuki S, Mase M, Umemura A, Nagai H. Serum neuron-specific enolase levels after subarachnoid hemorrhage. Surg Neurol. 1991;36(3):170–174. PMID: 1876966. doi: 10.1016/0090-3019(91)90108-l.

Hårdemark HG, Persson L, Bolander HG, Hillered L, Olsson Y, Påhlman S. Neuron-specific enolase is a marker of cerebral ischemia and infarct size in rat cerebrospinal fluid. Stroke. 1988;19(9):1140–1144. PMID: 3413812. doi: 10.1161/01.str.19.9.1140.

Wiesmann M, Missler U, Hagenström H, Gottmann D. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien). 1997;139(12):1155–1160. PMID: 9479422. doi: 10.1007/BF01410976.

Mehta T, Fayyaz M, Giler GE, Kaur H, Raikwar SP, Kempuraj D, et al. Current Trends in Biomarkers for Traumatic Brain Injury. Open Access J Neurol Neurosurg. 2020;12(4):86–94. PMID: 32775958.

Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT, et al. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma. 2000;17(2):113–122. PMID: 10709869. doi: 10.1089/neu.2000.17.113.

Rothoerl RD, Woertgen C, Holzschuh M, Metz C, Brawanski A. Rapid evaluation of S-100 serum levels. Case report and comparison to previous results. Brain Inj. 1999;13(5):387–391. PMID: 10367150. doi: 10.1080/026990599121584.

Hårdemark HG, Almqvist O, Johansson T, Påhlman S, Persson L. S-100 protein in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: relation to functional outcome, late CT and SPECT changes, and signs of higher cortical dysfunction. Acta Neurochir (Wien). 1989;99(3–4):135–144. PMID: 2788973. doi: 10.1007/BF01402322.

Dugan LL, Kim-Han JS. Astrocyte mitochondria in in vitro models of ischemia. J Bioenerg Biomembr. 200436(4):317–321. PMID: 15377865. doi: 10.1023/B:JOBB.0000041761.61554.44.

Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006;86(3):1009–1031. PMID: 16816144. doi: 10.1152/physrev.00049.2005.

Stranjalis G, Korfias S, Psachoulia C, Kouyialis A, Sakas DE, Mendelow AD. The prognostic value of serum S-100B protein in spontaneous subarachnoid haemorrhage. Acta Neurochir (Wien). 2007;149(3):231–237; dis. 237–238. PMID: 17242846. doi: 10.1007/s00701-006-1106-9.

Olivecrona M, Koskinen LD. Comment on: Early CSF and serum S 100B concentrations for outcome prediction in traumatic brain injury and subarachoid haemorrhage. Clin Neurol Neurosurg. 2016;150:197–198. PMID: 27569027. doi: 10.1016/j.clineuro.2016.07.026.

Tawk RG, Grewal SS, Heckman MG, Rawal B, Miller DA, Edmonston D, et al. The Relationship Between Serum Neuron-Specific Enolase Levels and Severity of Bleeding and Functional Outcomes in Patients With Nontraumatic Subarachnoid Hemorrhage. Neurosurgery. 2016;78(4):487–491. PMID: 26606669. doi: 10.1227/NEU.0000000000001140.

Quintard H, Leduc S, Ferrari P, Petit I, Ichai C. Early and persistent high level of PS 100β is associated with increased poor neurological outcome in patients with SAH: is there a PS 100β threshold for SAH prognosis? Crit Care. 2016;20:33. PMID: 26843206. doi: 10.1186/s13054-016-1200-1.

Abboud T, Mende KC, Jung R, Czorlich P, Vettorazzi E, Priefler M, et al. Prognostic Value of Early S100 Calcium Binding Protein B and Neuron-Specific Enolase in Patients with Poor-Grade Aneurysmal Subarachnoid Hemorrhage: A Pilot Study. World Neurosurg. 2017;108:669–675. PMID: 28943424. doi: 10.1016/j.wneu.2017.09.074.

Nylén K, Csajbok LZ, Ost M, Rashid A, Blennow K, Nellgård B, et al. Serum glial fibrillary acidic protein is related to focal brain injury and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(5):1489–1494. PMID: 17395862. doi: 10.1161/STROKEAHA.106.478362.

Balança B, Ritzenthaler T, Gobert F, Richet C, Bodonian C, Carrillon R, et al. Significance and Diagnostic Accuracy of Early S100B Serum Concentration after Aneurysmal Subarachnoid Hemorrhage. J Clin Med. 2020;9(6):1746. PMID: 32516898. doi: 10.3390/jcm9061746.

Weiss N, Sanchez-Peña P, Roche S, Beaudeux JL, Colonne C, Coriat P, et al. Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. Anesthesiology. 2006;104(4):658–666. PMID: 16571959. doi: 10.1097/00000542-200604000-00008.

Kopera M, Majchrzak H, Kaspera W. Prognostic factors in patients with intracerebral hematoma caused by ruptured middle cerebral artery aneurysm. Neurol Neurochir Pol. 1999;33(2):389–401. PMID: 10463253. (in Pol.)

Edouard AR, Felten ML, Hebert JL, Cosson C, Martin L, Benhamou D. Incidence and significance of cardiac troponin I release in severe trauma patients. Anesthesiology. 2004;101(6):1262–1268. PMID: 15564931. doi: 10.1097/00000542-200412000-00004.

Macrea LM, Tramèr MR, Walder B. Spontaneous subarachnoid hemorrhage and serious cardiopulmonary dysfunction – a systematic review. Resuscitation. 2005;65(2):139–148. PMID: 15866393. doi: 10.1016/j.resuscitation.2004.11.010.

Miss JC, Kopelnik A, Fisher LA, Tung PP, Banki NM, Lawton MT, et al. Cardiac injury after subarachnoid hemorrhage is independent of the type of aneurysm therapy. Neurosurgery. 2004;55(6):1244–1250; dis. 1250–1251. PMID: 15574206. doi: 10.1227/01.neu.0000143165.50444.7f.

Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet. 2002;360(9342):1267–1274. PMID: 12414200. doi: 10.1016/s0140-6736(02)11314-6.

Raabe A, Kopetsch O, Woszczyk A, Lang J, Gerlach R, Zimmermann M, et al. S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients. Neurol Res. 2004;26(4):440–445. PMID: 15198874. doi: 10.1179/016164104225015958.

Usui A, Kato K, Abe T, Murase M, Tanaka M, Takeuchi E. S-100ao protein in blood and urine during open-heart surgery. Clin Chem. 1989;35(9):1942–1944. PMID: 2776321.

Kusaka G, Ishikawa M, Nanda A, Granger DN, Zhang JH. Signaling pathways for early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2004;24(8):916–925. PMID: 15362722. doi: 10.1097/01.WCB.0000125886.48838.7E.

Heierhorst J, Kobe B, Feil SC, Parker MW, Benian GM, Weiss KR, et al. Ca2+/S100 regulation of giant protein kinases. Nature. 1996;380(6575):636–639. PMID: 8602266. doi: 10.1038/380636a0.

100

Hullin DA, Brown K, Kynoch PA, Smith C, Thompson RJ. Purification, radioimmunoassay, and distribution of human brain 14-3-2 protein (nervous-system specific enolase) in human tissues. Biochim Biophys Acta. 1980;628(1):98–108. PMID: 7357031. doi: 10.1016/0304-4165(80)90355-4.

101

Pelinka LE, Hertz H, Mauritz W, Harada N, Jafarmadar M, Albrecht M, et al. Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock. 2005;24(2):119–123. PMID: 16044081. doi: 10.1097/01.shk.0000168876.68154.43.

102

Sanchez-Peña P, Pereira AR, Sourour NA, Biondi A, Lejean L, Colonne C, et al. S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Crit Care Med. 2008;36(8):2267–2273. PMID: 18596638. doi: 10.1097/CCM.0b013e3181809750.

103

Ramont L, Thoannes H, Volondat A, Chastang F, Millet MC, Maquart FX. Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin Chem Lab Med. 2005;43(11):1215–1217. PMID: 16232088. doi: 10.1515/CCLM.2005.210.

104

Oertel M, Schumacher U, McArthur DL, Kästner S, Böker DK. S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J Clin Neurosci. 2006;13(8):834–840. PMID: 16931022. doi: 10.1016/j.jocn.2005.11.030.

105

Lefranc F, Golzarian J, Chevalier C, DeWitte O, Pochet R, Heizman C, et al. Expression of members of the calcium-binding S-100 protein family in a rat model of cerebral basilar artery vasospasm. J Neurosurg. 2002;97(2):408–415. PMID: 12186470. doi: 10.3171/jns.2002.97.2.0408.

106

Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16(4):562–572. PMID: 3895589. doi: 10.1161/01.str.16.4.562.

107

Lefournier V, Krainik A, Gory B, Derderian F, Bessou P, Fauvage B, et al. Perfusion CT to quantify the cerebral vasospasm following subarachnoid hemorrhage. J Neuroradiol. 2010;37(5):284–291. PMID: 20416949. doi: 10.1016/j.neurad.2010.03.003.

108

Sun H, Li W, Ma J, Liu Y, You C. CT perfusion diagnoses delayed cerebral ischemia in the early stage of the time-window after aneurysmal subarachnoid hemorrhage. J Neuroradiol. 2017;44(5):313–318. PMID: 28237366. doi: 10.1016/j.neurad.2016.12.013.

109

Перенести в английский вариант

110

Skvortsova VI, Stakhovskaya LV, Ayriyan NYu. Epidemiologiya insul’ta v Rossiyskoy Federatsii. Systemic Hypertension. 2005;(1):10–12. (In Russ.)

111

van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306–318. PMID: 17258671. doi: 10.1016/S0140-6736(07)60153-6.

112

Bowles E. Cerebral aneurysm and aneurysmal subarachnoid haemorrhage. Nurs Stand. 2014;28(34):52–59. PMID: 24749614. doi: 10.7748/ns2014.04.28.34.52.e8694.

113

Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. 2006;355(9):928–939. PMID: 16943405. doi: 10.1056/NEJMra052760.

114

115

Davydov VV, Komarov OS; Shestopalov AV (ed.). Biokhimiya nervnoy tkani. Moscow: Belyy veter Publ.; 2018. (in Russ.)

116

Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull. 1995;37(4):417–429. PMID: 7620916. doi: 10.1016/0361-9230(95)00040-2.

117

118

Michetti F, Miani N, De Renzis G, Caniglia A, Correr S. Nuclear localization of S-100 protein. J Neurochem. 1974;22(2):239–244. PMID: 4208418. doi: 10.1111/j.1471-4159.1974.tb11585.x.

119

Moss S. E. (ed.). The annexins. London&Chapel Hill: Portland Press; 1992.

120

Zimmer DB, Van Eldik LJ. Identification of a molecular target for the calcium-modulated protein S100. Fructose-1,6-bisphosphate aldolase. J Biol Chem. 1986;261(24):11424–11428. PMID: 3733759

121

122

Skripnikova EV, Gusev NB. Interaction of smooth muscle caldesmon with S-100 protein. FEBS Lett. 1989;257(2):380–382. PMID: 2531095. doi: 10.1016/0014-5793(89)81577-7.

123

124

125

126

127

128

129

Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease. Biochim Biophys Acta Mol Cell Res. 2020;1867(6):118677. PMID: 32057918. doi: 10.1016/j.bbamcr.2020.118677.

130

Astrand R, Undén J, Romner B. Clinical use of the calcium-binding S100B protein. Methods Mol Biol. 2013;963:373–384. PMID: 23296623. doi: 10.1007/978-1-62703-230-8_23.

131

132

133

Sosnovskiy AYu. Primenenie markera proteina S100 B v diagnostike i prognozirovanii iskhodov lecheniya cherepno-mozgovoy travmy : cand. med. sci. diss. synopsis. Moscow, 2014. (In Russ.) Available at: https://search.rsl.ru/ru/record/01005557615 [Accessed Dec 15, 2023]

134

135

136

Ishiguro Y, Kato K, Ito T, Nagaya M, Yamada N, Sugito T. Nervous system-specific enolase in serum as a marker for neuroblastoma. Pediatrics. PMID: 6356007. 1983;72(5):696–700.

137

Carney DN, Teeling M. Neuron-specific enolase: how useful as a cancer marker? Eur J Cancer Clin Oncol. 1988;24(5):825–828. PMID: 3049114. doi: 10.1016/0277-5379(88)90190-3.

138

139

140

141

Yilmaz S. Serum NO, S100B, NSE concentrations in migraine and their relationship. J Clin Neurosci. 2020;82(Pt A):32–35. PMID: 33317735. doi: 10.1016/j.jocn.2020.10.046.

142

143

144

145

Topuzova MP, Alekseeva TM, Panina EB, Vavilova TV, Kovzelev PD, Portik OA, et al. The possibility of using neuron-specific enolase as a biomarker in the acute period of stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(8–2):53–62. (In Russ.) doi: 10.17116/jnevro201911908253

146

147

148

Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res. 2000;25(9–10):1439–1451. PMID: 11059815. doi: 10.1023/a:1007677003387.

149

150

151

152

153

Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res. 2015;1600:17–31. PMID: 25543069. doi: 10.1016/j.brainres.2014.12.027.

154

Aebi U, Häner M, Troncoso J, Eichner R, Engel A. Unifying principles in intermediate filament (IF) structure and assembly. Protoplasma. 1988;145(2–3):73–81. doi: 10.1007/BF01349341

155

Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421–443. PMID: 21219963. doi: 10.1016/j.pneurobio.2011.01.005.

156

157

158

Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4(3):229–237. PMID: 7952264. doi: 10.1111/j.1750-3639.1994.tb00838.x.

159

160

Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32(12):638–647. PMID: 19782411. doi: 10.1016/j.tins.2009.08.002.

161

162

163

164

165

166

Marginean IC, Stanca DM, Vacaras V, Soritau O, Margiean M, Muresanu DF. Plasmatic markers in hemorrhagic stroke. J Med Life. 2011;4(2):148–150. PMID: 21776296.

167

168

169

170

171

172

173

174

van Bodegraven EJ, van Asperen JV, Robe PAJ, Hol EM. Importance of GFAP isoform-specific analyses in astrocytoma. Glia. 2019;67(8):1417–1433. PMID: 30667110. doi: 10.1002/glia.23594.

175

176

177

178

179

180

181

182

183

Mabe H, Suzuki S, Mase M, Umemura A, Nagai H. Serum neuron-specific enolase levels after subarachnoid hemorrhage. Surg Neurol. 1991;36(3):170–174. PMID: 1876966. doi: 10.1016/0090-3019(91)90108-l.

184

185

186

Mehta T, Fayyaz M, Giler GE, Kaur H, Raikwar SP, Kempuraj D, et al. Current Trends in Biomarkers for Traumatic Brain Injury. Open Access J Neurol Neurosurg. 2020;12(4):86–94. PMID: 32775958.

187

188

189

190

Dugan LL, Kim-Han JS. Astrocyte mitochondria in in vitro models of ischemia. J Bioenerg Biomembr. 200436(4):317–321. PMID: 15377865. doi: 10.1023/B:JOBB.0000041761.61554.44.

191

Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006;86(3):1009–1031. PMID: 16816144. doi: 10.1152/physrev.00049.2005.

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

Usui A, Kato K, Abe T, Murase M, Tanaka M, Takeuchi E. S-100ao protein in blood and urine during open-heart surgery. Clin Chem. 1989;35(9):1942–1944. PMID: 2776321.

207

208

Heierhorst J, Kobe B, Feil SC, Parker MW, Benian GM, Weiss KR, et al. Ca2+/S100 regulation of giant protein kinases. Nature. 1996;380(6575):636–639. PMID: 8602266. doi: 10.1038/380636a0.

209

210

211

212

213

214

215

Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16(4):562–572. PMID: 3895589. doi: 10.1161/01.str.16.4.562.

216

217

The authors declare that there are no conflicts of interest present.